Search by keywords: Connect with us Stay Informed. Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters. Newsletter Sign Up 1844 News Items found Talking About a Lung Cancer Diagnosis With Family, Friends, and Others Monday, November 10, 2025 Learn how to talk about your lung cancer diagnosis with family, friends and others — including questions about smoking. MSK Researchers Make Strides Against VEXAS Syndrome Monday, November 3, 2025 VEXAS syndrome is a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men over 50. Now, MSK researchers are shedding new light on its mechanisms and laying the groundwork for potential targeted treatments. MSK Research Highlights, October 31, 2025 Friday, October 31, 2025 New MSK research uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative breast cancer among Black women; shows a web-based system could help head-and-neck cancer survivors report their concerns; and finds adding immunotherapy can boost the effectiveness for hard-to-treat follicular lymphomas. Feature The Truth About PSA Tests and Prostate Cancer Screening Thursday, October 30, 2025 PSA testing is an important part of screening for prostate cancer, when it’s used the right way. Learn the truth dispelling seven myths about the PSA test. FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia Wednesday, October 29, 2025 Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations. New Treatment for Metastatic (Stage 4) Melanoma: TIL Immunotherapy Tuesday, October 28, 2025 After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy. The Latest on Prostate Cancer Checkpoint Inhibitor Immunotherapy at MSK Friday, October 24, 2025 Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy. New Targeted Therapy, Ulixertinib, Shows Promise for Histiocytosis, a Rare Blood Cancer Thursday, October 23, 2025 Learn how MSK research on a family of rare blood cancers called histiocytosis is leading to new targeted therapies that benefit patients. ESMO 2025: MSK Presents New Research, Including Latest on Lung and Pancreatic Cancer Treatments Tuesday, October 21, 2025 MSK highlights from the recent European Society for Medical Oncology (ESMO) Congress include promising findings on new lung, pancreatic, and colorectal cancer treatments and new insights for how molecular testing can guide personalized medicine. Article Latest Research Into Overcoming Resistance to Breast Cancer Targeted Therapies Thursday, October 16, 2025 Learn how MSK's researchers are making important strides in overcoming breast cancer resistance. Pagination Load More Book traversal links for Newsroom Previous Newsroom Next Cancer Vaccine Could Prevent Neuroblastoma From Returning After Antibody Treatment